– Leading cause of long-term disability
~$240B annual US cost in 2030
BB-031 has demonstrated superiority to TPA across multiple murine and canine preclinical models while BB-025 expands the clinical utility allowing for hemostatic mod.
Improved risk-benefit profile over SOC allows:
vWF drives both clot formation but also pathological expansion.